Skip to main content

status

  • Operating in maintenance mode.

340.682.01
Pharmacoepidemiology Methods

Location
East Baltimore
Term
2nd Term
Department
Epidemiology
Credit(s)
3
Academic Year
2025 - 2026
Instruction Method
In-person
Class Time(s)
Tu, Th, 1:30 - 2:50pm
Auditors Allowed
Yes, with instructor consent
Available to Undergraduate
No
Grading Restriction
Letter Grade or Pass/Fail
Course Instructor(s)
Contact Name
Frequency Schedule
Every Year
Prerequisite
340.601 or 340.751 or 340.721
Enrollment Restriction
graduate students only
Description
Introduces the key elements of pharmacoepidemiology. Explores the utilization and effects of drugs in large numbers of people. Discusses the application of epidemiological methods to pharmacological issues. Focuses heavily on questions of drug safety and effectiveness, concentrating on clinical patient outcomes and on evaluating the use of therapies. Applies the research methods of clinical epidemiology (e.g., randomized trials, cohort studies, case-control studies, use of secondary data, attention to biases and confounding) to the content area of pharmacology (e.g., determinants of beneficial and adverse drug effects, effects of patient heterogeneity on drug effect, effects of non-adherence, active and passive surveillance for adverse events).
Learning Objectives
Upon successfully completing this course, students will be able to:
  1. Describe key historical events in drug regulation history in the US
  2. Compare and contrast different data sources for pharmacoepidemiology studies and their strengths and limitations
  3. Assess validity of data and approaches to operationalizing exposures and outcomes
  4. Apply diverse epidemiological designs to answer questions about drug effectiveness and drug safety
  5. Apply methods for active and passive pharmacovigilance for adverse drug events
Upon successfully completing this course, students will be able to:
Methods of Assessment
This course is evaluated as follows:
  • 18% Assignments
  • 30% Midterm
  • 40% Final Exam
  • 12% Discussion